Theratechnologies receives tesamorelin patent in BTheratechnologies receives tesamorelin patent in Brazil
2009-12-29 13:20 ET - News Release
Ms. Andrea Gilpin reports
THERATECHNOLOGIES RECEIVES PATENT PROTECTION IN BRAZIL FOR TESAMORELIN
The Brazil Patent and Trademark Office has issued Theratechnologies Inc. patent No. 9608799-4 entitled "chimeric fatty body-pro-GRF analog with increased biological potency and pharmaceutical formulation" for its lead compound, tesamorelin. The granting of this patent provides protection in Brazil until December, 2019.
"This patent aligns us well in executing one of our top priorities, which is to expand commercialization into various geographies for tesamorelin in HIV-associated lipodystrophy," commented Yves Rosconi, president and chief executive officer of Theratechnologies. "Brazil is a country where there are patients in need and where we can leverage the work already completed for the U.S. regulatory agency. The patent announced today solidifies our approach and reinforces Brazil as an attractive territory for potential partners," concluded Mr. Rosconi.
About HIV-associated lipodystrophy
Several factors including the anti-retroviral drug regimen and the virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients and discourage HIV treatment adherence.
We seek Safe Harbor.